1. Bohring A., Silengo M., Lerone M., Superneau D.W., Spaich C., Braddock S.R., Poss A., Opitz J.M. Severe end of Opitz trigonocephaly (C) syndrome or new syndrome? I am // J Med Genet. 1999. No 85. P. 438–446.
2. Zhao J., Hou Y., Fang F., Ding C., Yang X., Li J., Cui D., Cao Z., Zhang H. Novel truncating mutations in ASXL1 identified in two boys with Bohring – Opitz syndrome // Eur J Med Genet. 2021. No 64. P. 104155. DOI: 10.1016/j.ejmg.2021.104155.
3. Arunachal G., Danda S., Omprakash S., Kumar S. A novel de-novo frameshift mutation of the ASXL1 gene in a classic case of Bohring-Opitz syndrome // Clin Dysmorphol. 2016. Vol. 3, Is. 25. P. 101–105. DOI: 10.1097/MCD.0000000000000126.
4. Hoischen A., van Bon B.W., Rodriguez-Santiago B., Gilissen C., Vissers L.E., de Vries P., Janssen I., van Lier B., Hastings R., Smithson S.F., Newbury-Ecob R., Kjaergaard S., Goodship J., McGowan R., Bartholdi D., Rauch A., Peippo M., Cobben J.M., Wieczorek D., Gillessen-Kaesbach G., Veltman J.A., Brunner H.G., de Vries B.B. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome // Nat Genet. 2011. Vol. 8, Is. 43. P. 729–731. DOI: 10.1038/ng.868.
5. Carlston C.M., O’Donnell-Luria A.H., Underhill H.R., Cummings B.B., Weisburd B., Minikel E.V., Birnbaum D.P., Consortium E.A., Tvrdik T., MacArthur D.G., Mao R. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring – Opitz Syndrome // Human Mutation. 2017. Vol. 38 (5). P. 517–523. DOI: 10.1002/humu.23203.
6. Richards S., Aziz N., Bale S., Bick D., Das S., Rehm H.L., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., Voelkerding K., Rehm H.L. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology // Genetics in Medicine. 2015. Vol. 17 (5). P. 405–423. DOI: 10.1038/gim.2015.30.
7. Gelsi-Boyer V., Brecqueville M., Devillier R., Murati A., Mozziconacci M.J., Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases // Journal of Hematology Oncology. 2012. Vol. 5. P. 12–19. DOI: 10.1186/1756-8722-5-12.
8. Zhang P., Xing C., Rhodes S.D., He Y., Deng K., Li Z., He F., Zhu C., Nguyen L., Zhou Y., Chen S., Mohammad K., Guise T.A., Abdel-Wahab O., Xu M., Wang Q.-F., Yang F.-C. Loss of Asxl1 alters self-renewal and cell fate of bone marrow stromal cell, leading to bohring-opitz-like syndrome in mice // Stem Cell Rep. 2016. Vol. 6. P. 914–925. DOI: 10.1016/j.stemcr.2016.04.013.
9. Hastings R., Cobben J.-M., Gillessen-Kaesbach G., Goodship J., Hove H., Kjaergaard S., Newbury-Ecob R., Kemp H., Kingston H., Lunt P., Mansour S., McGowan R., Metcalfe K., Murdoch- Davis C., Ray M., Rio M., Smithson S., Tolmie J., Turnpenny P., van Bon B., Wieczorek D., Newbury-Ecob R. Bohring – Opitz (Oberklaid–Danks) syndrome: clinical study, review of the literature, and discussion of possible pathogenesis // European Journal of Human Genetics. 2011. Vol. 19 (5). P. 513–519. DOI: 10.1038/ejhg.2010.234.
10. Dangiolo S.B., Wilson A., Jobanputra V., Anyane-Yeboa K. Bohring – Opitz syndrome (BOS) with a newASXL- 1pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome // American Journal of Medical Genetics Part A. 2015. Vol. 167 (12). P. 3161–3166. DOI: 10.1002/ajmg.a.37342.
11. Russell B., Johnston J.J., Biesecker L.G., Kramer N., Pickart A., Rhead W., Graham J.M., Kramer N., Pickart A., Rhead W., Tan W.-H., Brownstein C.A., Clarkson L.K., Dobson A., Rosenberg A.Z., Schrier Vergano S.A., Helm B.M., Rachel E. Harrison R.E., Graham J.M. Clinical management of patients with ASXL1mutations and Bohring – Opitz syndrome, emphasizing the need for Wilms tumor surveillance // American Journal of Medical Genetics Part A. (2015). Vol. 167 (9). P. 2122–2131. DOI: 10.1002/ajmg.a.37131.
12. Bruel A.-L., Bigoni S., Kennedy J., Whiteford M., Buxton C., Parmeggiani G., Wherlock M., Woodward G., Greenslade M., Williams M., St-Onge J., Ferlini A., Garani G., Ballardini E., van Bon B.W., Acuna-Hidalgo R., Bohring A., Deleuze J.-F., Boland A., Meyer V., Olaso R., Ginglinger E., Study D., Rivière J.-B., Brunner H.G., Hoischen A., Newbury-Ecob R., Faivre L., Thauvin- Robinet C., Thevenon J. Expanding the clinical spectrum of recessive truncating mutations of KLHL7 to a Bohring – Opitzlike phenotype // Journal of Medical Genetics. 2017. Vol. 54. P. 830–835. DOI: 10.1136/jmedgenet-2017-104748.
13. Cheraghi S., Moghbelinejad S., Najmabadi H., Kahrizi K., Najafipour R. A novel PTC mutation in the BTBdomain of KLHL7 gene in two patients with Bohring – Opitz syndrome-like features // European Journal of Medical Genetics. 2020. Vol. 63. P. 103. DOI: 10.1016/j.ejmg.2020.103849.